GlassScriptPhysician profile
Mary Alice E Bailey
NPI 1952694697
$6,876.76
in general payments reported to CMS, 2019-2025
39 companies · $994 in 2025
The $994 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $655 · 2021: $1,001 · 2022: $1,026 · 2023: $982 · 2024: $1,012 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,987.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,199.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,166.28 | 2019-2025 | |
| Abbvie INC. | $797.36 | 2021-2025 | Ubrelvy, Qulipta |
| Celgene Corporation | $575.44 | 2019 | |
| Lilly USA, LLC | $370.96 | 2019-2025 | Jardiance, Mounjaro, Trulicity |
| Abbott Laboratories | $367.99 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $362.46 | 2022-2025 | |
| Glaxosmithkline, LLC. | $286.15 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.15 | 2019-2022 | |
| Amarin Pharma, INC. | $138.42 | 2019-2023 | |
| Esperion Therapeutics, INC. | $98.39 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $98.13 | 2019-2023 | Farxiga |
| Amgen INC. | $89.47 | 2019-2025 | Krystexxa |
| Exact Sciences Corporation | $86.03 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biogen, INC. | $80.61 | 2025 | Tysabri, Vumerity |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Alice Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.